Sepsis Diagnostics Market Analysis by Product (Assay Kits & Reagents, Blood Culture Media); by Technology (Microbiology, Immunoassays, and Flow Cytometry); by Pathogen (Bacterial Sepsis, Fungal Sepsis, and Others); and by Testing Type (Laboratory Tests and POC Testing) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2035
Buy Now Report ID: 4869 | Published Date: Apr 30, 2023
Sepsis Diagnostics Market size is estimated to reach ~USD 6 Billion by the end of 2035 by growing at a CAGR of ~11.90% over the forecast period, i.e., 2023 – 2035. In addition to this, in the year 2022, the market size of sepsis diagnostics was ~USD 2 Billion. The growth of the market can be attributed to the increasing number of elderly people who are prone to sepsis. Further, the growing technological advancements in the field of sepsis diagnostics are expected to add to the market growth. The United States Food and Drug Administration, FDA, granted marketing authorization to Immunoexpress Inc.'s SeptiCyte RAPID in December 2021. In October 2021, Prenosis Inc. extended an existing agreement with Roche Diagnostics to accelerate the clinical diagnosis of sepsis. Prenosis, Inc. is a precision diagnostic company that uses AI in order to help diagnose patients more accurately.
In addition to these, factors that are believed to fuel the market growth of sepsis diagnostics include the increase in sepsis cases, the increased burden of hospital-acquired infections, the rising number of pneumonia cases, a higher level of sepsis treatment, and an increase in funding for research related to sepsis. Increased use of sepsis diagnostic products is expected to contribute to market growth. In addition, a new intervention to actively prevent, treat and evaluate sepsis in pregnant women was funded by more than GBP 3 million in June 2021.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~11.90% |
|
Base Year Market Size (2022) |
~ USD 2 Billion |
|
Forecast Year Market Size (2035) |
~ USD 6 Billion |
|
Regional Scope |
|
Growth Drivers
Challenges
The global market is segmented and analyzed for demand and supply by product into IBS with assay kits & reagents and blood culture media. Out of the two types of sepsis diagnostics, the blood culture media segment is estimated to gain the largest market share of about ~42% in the year 2035. The growth of the segment can be attributed to the increasing convenience and cost-effectiveness of this mode of testing. Further, the growing use of blood culture media by hospitals and pathology laboratories is also expected to contribute to the growth of the segment. For instance, it was found that the Sepifast system, which uses PCR techniques, had a better diagnostic performance when compared to blood cultures during an experimental study on patients from Thailand suffering from sepsis. As a result of increasing awareness about health care and the growing number of surgical procedures, it is also noted that instrument segments will continue to grow over the forecast period. For example, in September 2019 Guthrie, a U.S.-based Integrated Health System, started to use Wolters Kluwer Point of Care advisors for detecting and treating Sepsis at four hospitals within the area. All these factors are anticipated to contribute to the growth of the segment.
The global sepsis diagnostics market is also segmented and analyzed for demand and supply by technology into microbiology, immunoassays, and flow cytometry. Amongst these three segments, the microbiology segment is expected to garner a significant share of around ~45% in the year 2035. It is based on the fact that microbiological technology makes use of culture media tests to detect and identify sepsis organisms in a precise manner. Moreover, the growing segment is being driven by New Strategic Initiatives undertaken by major players. For instance, in April 2019, BD introduced the new BACTEC plasma quality monitoring media to help identify and reduce sepsis incidence among patients who receive blood transfusions. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global sepsis diagnostics market includes the following segments:
|
By Product |
|
|
By Technology
|
|
|
By Pathogen |
|
|
By Testing Type |
|
The market share of sepsis diagnostics in North America, amongst the market in all the other regions, is projected to be the largest with a share of about ~39% by the end of 2035. The growth of the market can be attributed majorly to the increasing and developed healthcare infrastructure in the region. This has led to an increase in the number of advanced diagnostic equipment and programs being used across the region. Furthermore, the market's growth is supported by a high presence of key players and an adequate reimbursement framework across that region. Moreover, demand for new diagnostics solutions is expected to rise due to a high incidence of sepsis and infectious diseases. For instance, according to the Centers for Disease Control and Prevention, in August 2021, approximately 1.7 million adults in America develop sepsis, and nearly 270,000 Americans die due to sepsis. It was also found that 1 in 3 patients who die in a hospital have sepsis. Hence, its diagnosis will increase and the market will grow as a result of the high number of cases in the country. The market will also be supported by increasing investments in research and development to diagnose sepsis. For example, Cytovale Inc., in April 2020, expanded its partnership with the Biomedical Advanced Research and Development Authority, BARDA, to diagnose sepsis in patients with potential respiratory infections, including COVID-19. Research costs are estimated to be US$1.2 billion. 5.9 million.
The Asia Pacific sepsis diagnostics market is estimated to be the second largest, registering a significant share by the end of 2035. The growth of the market can be attributed majorly to the increasing research efforts by key players in the last few years that have fueled a growing need to rapidly diagnose sepsis. For instance, Cytovale Inc. announced a partnership with the Biomedical Advanced Research and Development Authority, BARDA, for the diagnosis of sepsis in patients with infectious respiratory disease, including COVID-19, in April 2020. In addition to a contribution of 3.83 million by BARDA, the research was expected to amount to US$ 5.9 million. In addition, the region's launch of effective treatments and clinical trials are also anticipated to boost the market growth during the forecast period.
Further, the sepsis diagnostics market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2035. The growth of the market can be attributed majorly to the increasing number of fatalities caused by sepsis in the region. There is a series of trials in order to reduce the number of diseases that have been caused, as well as by applying novel diagnostics and therapeutic approaches. The growing incidence of sepsis, coupled with a rising number of diagnostic laboratories across the country, is driving the market. For instance, the Pasteur Institute, a non-profit foundation dedicated to studying vaccines and diseases reports that the sepsis-related death rate in France is nearly 27%. All these factors contribute to the growth of the market.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: Increasing prevalence of hospital-acquired infections, the rising burden of sepsis in the world, and rising diagnostic developments are the major factors driving the market growth.
Ans: The market size of sepsis diagnostics is anticipated to attain a CAGR of ~11.90% over the forecast period, i.e., 2023 – 2035.
Ans: High cost of diagnostics devices, and the shortage of skilled healthcare professionals are estimated to be the growth hindering factors for the market expansion.
Ans: The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Ans: The major players in the market are bioMérieux SA, Becton, Dickinson and Company, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Danaher Corporation (Beckman Coulter, Inc.), Cepheid, Beckman Coulter, Inc., Luminex Corp., Bruker Corp., Amara Health Analytics
Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by product, technology, pathogen, testing type, and by region.
Ans: The blood culture media segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
